IBRX
Immunitybio Inc
8.60$
-7.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.6% | 81.1% | 64.6% | 52.9% | 48.8% | 39.0% | 50.5% | 71.3% | 38.8% | 58.3% | 48.2% | 62.7% | |
| 97.2% | 48.0% | 2.5% | 9.5% | 9.2% | 10.8% | 15.8% | 38.6% | 28.9% | 52.6% | 37.5% | 17.6% | |
| 97.2% | 80.2% | 62.7% | 51.2% | 40.8% | 36.1% | 43.4% | 67.6% | 29.6% | 52.8% | 39.1% | 48.4% | |
| 0.2% | 0.5% | 0.8% | 0.5% | 6.7% | 0.2% | 0.9% | 0.3% | 0.5% | 0.6% | 0.7% | 8.5% | |
| – | – | – | 0.0% | – | – | – | – | 7.3% | 0.0% | 2.2% | 0.2% | |
| – | – | 6.1% | 30.6% | 16.3% | 19.4% | 13.1% | 17.7% | 39.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | 0.2% | 0.2% | |
| 1.4% | 2.0% | 1.6% | 1.1% | 6.6% | 8.4% | 0.7% | 0.3% | 5.5% | 3.4% | 3.9% | 2.6% | |
| 4.0% | 3.0% | 7.6% | 12.6% | 19.8% | 15.7% | 153.5% | 152.0% | 224.1% | 216.2% | 227.5% | 199.5% | |
| 4.0% | 1.7% | 4.0% | 8.3% | 15.0% | 8.1% | 30.8% | 78.7% | 138.2% | 11.6% | 14.3% | 12.3% | |
| 0.4% | 0.1% | 0.1% | 0.1% | 0.5% | 2.8% | 2.3% | 64.5% | 119.9% | 1.0% | 1.9% | 1.9% | |
| 1.9% | 0.6% | 1.3% | 2.3% | 1.5% | 1.2% | 5.2% | 2.4% | 5.8% | 1.8% | 1.8% | 1.4% | |
| – | – | – | – | – | – | 114.9% | 65.3% | 66.6% | 135.1% | 120.6% | 95.1% | |
| 96.0% | 97.0% | 92.4% | 87.4% | 80.2% | 84.3% | -54.1% | -51.6% | -123.4% | -116.4% | -127.7% | -99.5% | |
| -20.9% | -68.3% | -121.9% | -199.1% | -327.0% | -462.7% | -729.6% | -418.4% | -656.4% | -587.1% | -881.4% | -742.5% | |
| 519.0% | 78.0% | 103.3% | 128.7% | 178.6% | 267.7% | 173.1% | 83.0% | 110.4% | 100.8% | 182.9% | 183.3% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.